We are live on ! Find out more
IMRX icon

Immuneering
IMRX

37 hedge funds and large institutions have $65.7M invested in Immuneering in 2022 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 7 increasing their positions, 21 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

5.56% less ownership

Funds ownership: 51.6% → 46.04% (-5.6%)

26% less funds holding

Funds holding: 50 → 37 (-13)

62% less capital inflows, than outflows

Capital inflows: $5.44M | Capital outflows: $14.4M

67% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 18

67% less repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 21

Holders
37
Holders Change
-13
Holders Change %
-26%
% of All Funds
0.62%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
7
Reduced
21
Closed
18
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$3.08M
2
Buckingham Strategic Wealth
Buckingham Strategic Wealth
Missouri
+$1.07M
3
Millennium Management
Millennium Management
New York
+$533K
4
Citadel Advisors
Citadel Advisors
Florida
+$212K
5
Bridgeway Capital Management
Bridgeway Capital Management
Texas
+$186K

Top Sellers

Rank Fund Capital Flow
1
Perceptive Advisors
Perceptive Advisors
New York
-$4.41M
2
BlackRock
BlackRock
New York
-$4.09M
3
Geode Capital Management
Geode Capital Management
Massachusetts
-$874K
4
State Street
State Street
Massachusetts
-$808K
5
Northern Trust
Northern Trust
Illinois
-$682K

IMRX Hedge Fund Activity: Q2 2022 in Review

37 of the 5,963 institutional investors tracked by Wall St. Rank reported a position in Immuneering (IMRX) for Q2 2022, worth a combined $65.7M — down 25% from $88.1M a quarter earlier.

Sellers outnumbered buyers: 18 funds closed out of IMRX and 6 opened new positions — a net loss of 12 holders — while 21 trimmed existing stakes and 7 added.

The largest buyer was T. Rowe Price Associates, adding an estimated $3.08M. The largest seller was Perceptive Advisors, exiting entirely with an estimated $4.41M sold.

  • 37 institutional investors held Immuneering (IMRX) as of Q2 2022, down from 50 in Q1 2022.
  • Funds reported $65.7M of Immuneering stock for Q2 2022, down 25% quarter-over-quarter.
  • 6 funds opened new Immuneering positions in Q2 2022 and 18 closed out, a net change of -12 holders.
  • The largest Immuneering buyer in Q2 2022 was T. Rowe Price Associates, an estimated $3.08M added.
  • The largest Immuneering seller in Q2 2022 was Perceptive Advisors, an estimated $4.41M sold.

Based on aggregated 13F filings for Q2 2022.